125 related articles for article (PubMed ID: 14578562)
21. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma.
Fung AT; Reid SE; Jones MP; Healey PR; McCluskey PJ; Craig JC
Br J Ophthalmol; 2007 Jan; 91(1):62-8. PubMed ID: 16956912
[TBL] [Abstract][Full Text] [Related]
24. [Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].
Araie M; Yamazaki Y; Sugiyama K; Kuwayama Y; Tanihara H
Nippon Ganka Gakkai Zasshi; 2012 Oct; 116(10):955-66. PubMed ID: 23285843
[TBL] [Abstract][Full Text] [Related]
25. Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops.
Napolitano M; Potestio L; Castagliola C; Fabbrocini G; Patruno C
Contact Dermatitis; 2021 Sep; 85(3):382-384. PubMed ID: 33861874
[No Abstract] [Full Text] [Related]
26. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
[TBL] [Abstract][Full Text] [Related]
27. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
28. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
Katz G; Dubiner H; Samples J; Vold S; Sall K
JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
[TBL] [Abstract][Full Text] [Related]
29. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.
Konstas AG; Katsimpris IE; Kaltsos K; Georgiadou I; Kordelou A; Nelson LA; Stewart WC
Eye (Lond); 2008 Nov; 22(11):1391-7. PubMed ID: 17571086
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
31. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
[TBL] [Abstract][Full Text] [Related]
32. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
Hommer A; Kapik B; Shams N;
Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
[TBL] [Abstract][Full Text] [Related]
33. The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
Stewart WC; Stewart JA; Day DG; Jenkins J
Acta Ophthalmol Scand; 2004 Apr; 82(2):161-5. PubMed ID: 15043534
[TBL] [Abstract][Full Text] [Related]
34. The teardrop sign: a rare dermatological reaction to brimonidine.
Scruggs JT; Whiteside-Michel J; Brodsky MC
Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417
[No Abstract] [Full Text] [Related]
35. Brimonidine-induced unilateral ocular lichen planus: a case report.
Ventura-Abreu N; Fernández-Aceñero MJ; Narváez-Palazón C; Romo-López A
Arq Bras Oftalmol; 2019; 82(3):236-238. PubMed ID: 30916215
[TBL] [Abstract][Full Text] [Related]
36. Periocular allergic contact dermatitis caused by brinzolamide.
Navarro-Triviño FJ; Ruiz-Villaverde R
Contact Dermatitis; 2021 Apr; 84(4):274-276. PubMed ID: 33094487
[No Abstract] [Full Text] [Related]
37. [Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
Shi JM; Jiang YQ
Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):263-6. PubMed ID: 12575311
[TBL] [Abstract][Full Text] [Related]
38. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
[TBL] [Abstract][Full Text] [Related]
39. Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring.
Hermann MM; Bron AM; Creuzot-Garcher CP; Diestelhorst M
J Glaucoma; 2011 Oct; 20(8):502-8. PubMed ID: 20852438
[TBL] [Abstract][Full Text] [Related]
40. Contact allergy to trometamol.
Bohn S; Hurni M; Bircher AJ
Contact Dermatitis; 2001 May; 44(5):319. PubMed ID: 11382218
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]